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Ginsenoside-Rb1 is a chemically pure steroid glycoside 
from the root of Panax ginseng, which has a 3000-year 
history of medicinal use in the Orient. 
Betts et al (2011) reported that Rb1 inhibits vascular 
endothelial growth factor (VEGF) release by retinal 
pigment epithelial cells, which is a major source of VEGF 
in the eye (1). Vascular endothelial growth factor is a 
proangiogenic cytokine that contributes significantly to 
pathological retinal and choroidal neovascularization in 
association with diabetic retinopathy and age-related 
macular degeneration. It is, therefore, highly relevant to 
study the action of Rb1 inhibition of VEGF release and to 
further explore an effective method to enhance such an 
action of Rb1. One possible approach is the chemical 
modification of this steroid glycoside to increase its 
potency. 
There have been several reports focused on the structure 
vs. activity relations (SAR) of ginsenosides and their 
derivatives. By simple acylation of the panaxadiol, an 
analog of ginsenoside, its anti-tumor activity was 
significantly enhanced, compared with the non-acylated 
parent ((Note: Anti-tumor activity was measured by the 
decrease in the viability of ovarian cancer cell ES-2, 
osteosarcoma cell U2-OS, human hepatocellular 
carcinoma cells HepG2 and human lung tumor cell A549) 
(2). 
Using a different cancer cell line (lung fibroblast), Dong et 
al. (2011) noted that the removal of the sugar moiety (by 
hydrolysis) significantly increased its cytotoxic potency, 
based on MTT assays, to measure viable cell numbers (6). 
Du et al.(2011) also reported that protopanaxadiol with 
acetyl substitutions had a significant increase in its 
antiproliferative effect on three human cell types 
(colorectal, breast and colon cancer cells) and they 
furthermore attributed this action to an increase of 
programmed cell death (apoptosis) (3). 
Such SAR reports are not limited to chemical 
modification of ginsenosides leading to inhibition of 
cancer cell proliferation only. Wei et al (2009) reported 
that oxidation of panxadiol leads to triperpene 
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derivatives with a significant increase in the ability to 
inhibit the HIV-1 protease enzyme, which is required for 
maturation and infectivity of the HIV virus (4). Finally, 
Wang et al. (2010) reported that epimeric derivatives 
from 20(S)-panaxadiol have an enhanced 
pharmacological action to ameliorate myocardial injury 
induced by isoproterenol in a rat model (5). 
Recently, there has been an increased interest in SAR in 
medicinal chemistry. These reports provide further 
evidence for the need of exploring how chemically 
modified ginsenosides may enhance inhibition of VEGF in 
ocular and other cell types. Such discoveries will provide 
new knowledge for novel intervention methods to treat 
angiogenic diseases such as diabetic retinopathy, AMD 
and cancer. 
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